阿达木单抗和英夫利昔单抗治疗难治性肠白塞病的真实世界疗效。
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
机构信息
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
出版信息
Dig Liver Dis. 2019 Jul;51(7):967-971. doi: 10.1016/j.dld.2018.10.024. Epub 2019 Feb 19.
BACKGROUND
Anti-tumor necrosis factor-α agents are important for managing refractory intestinal Behçet's disease. Few studies have reported the efficacy of anti-tumor necrosis factor-α monoclonal antibodies for intestinal Behçet's disease due to its rarity.
AIMS
The aim was to examine the efficacy of anti-tumor necrosis factor-α antibodies for intestinal Behçet's disease in real-world practice.
METHODS
This was a retrospective review of medical records at 4 hospitals in Japan. Global gastrointestinal symptom and endoscopic assessment scores were analyzed in intestinal Behçet's disease patients given anti-tumor necrosis factor-α agents at 3 and 12 months after the start of therapy.
RESULTS
Of 53 intestinal Behçet's disease patients, 22 received anti-tumor necrosis factor-α monoclonal antibody treatment. At the first line, 14 were given adalimumab, and 8 were given infliximab. After 3 and 12 months of treatment, 7 and 11 patients showed complete response of gastrointestinal symptom scores, respectively, and 5 and 9 showed complete remission of the endoscopic assessment score, respectively. Three patients switched anti-tumor necrosis factor-α agents.
CONCLUSION
Anti-tumor necrosis factor-α monoclonal antibodies are effective for refractory intestinal Behçet's disease in real-world situations. Switching anti-tumor necrosis factor-α agents may be useful for failure of first-line anti-tumor necrosis factor-α therapy in some refractory cases.
背景
抗肿瘤坏死因子-α 制剂对于治疗难治性肠道贝赫切特病至关重要。由于肠道贝赫切特病较为罕见，鲜有研究报道抗肿瘤坏死因子-α 单克隆抗体治疗肠道贝赫切特病的疗效。
目的
本研究旨在评估抗肿瘤坏死因子-α 抗体治疗真实世界中肠道贝赫切特病的疗效。
方法
这是在日本 4 家医院进行的一项回顾性病历研究。对开始治疗后 3 个月和 12 个月接受抗肿瘤坏死因子-α 制剂治疗的肠道贝赫切特病患者的全球胃肠道症状和内镜评估评分进行分析。
结果
在 53 例肠道贝赫切特病患者中，22 例接受了抗肿瘤坏死因子-α 单克隆抗体治疗。一线治疗中，14 例患者接受阿达木单抗治疗，8 例患者接受英夫利昔单抗治疗。治疗 3 个月和 12 个月后，分别有 7 例和 11 例患者胃肠道症状评分完全缓解，分别有 5 例和 9 例患者内镜评估评分完全缓解。3 例患者更换了抗肿瘤坏死因子-α 制剂。
结论
在真实世界中，抗肿瘤坏死因子-α 单克隆抗体对难治性肠道贝赫切特病有效。对于一些难治性病例，一线抗肿瘤坏死因子-α 治疗失败时，更换抗肿瘤坏死因子-α 制剂可能有用。
Zotero 插件